Chemokine Receptor Antagonist Pipeline Insights, 2019 - ResearchAndMarkets.com

DUBLIN--()--The "Chemokine Receptor Antagonist - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Chemokine Receptor Antagonist - Pipeline Insight, 2019 report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Chemokine Receptor Antagonist development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Chemokine Receptor Antagonist - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Chemokine Receptor Antagonist

The report assesses the active Chemokine Receptor Antagonist pipeline products by developmental stage, product type, molecule type, and administration route.

Key Topics Covered:

1. Report Introduction

2. Chemokine Receptor Antagonist - Overview

3. Pipeline Therapeutics

4. Comparative Analysis

5. Chemokine Receptor Antagonist Pipeline Products in Clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

6. Chemokine Receptor Antagonist Pipeline Products in Non-clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment: Active Products

  • Pipeline Assessment by Route of Administration
  • Pipeline Assessment by Stage and Route of Administration
  • Pipeline Assessment by Molecule Type
  • Pipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

  • Product Description
  • Research and Development
  • Product Development Activities
  • Reason for dormancy/discontinuation

Companies Mentioned

  • ChemoCentryx
  • Bristol-Myers Squibb
  • ChemoCentryx
  • Millennium Pharmaceuticals
  • Pfizer
  • EPIX Pharmaceuticals
  • Dimerix Bioscience
  • Takeda
  • Sorrento Therapeutics
  • Osprey Pharmaceuticals
  • Osprey Pharmaceuticals
  • RAPID Pharmaceuticals
  • Bayer HealthCare

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/grd3t4/chemokine?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs